CD274 and non-small cell lung carcinoma: Thalidomide has been shown to suppress angiogenic process and immune evasion of NSCLC cells by influencing the expression of VEGFA and PD-1/PD-L1 via affecting FGD5-AS1/miR-454–3p/ZEB1 axis (71).